Update on immune‐based therapy strategies targeting cancer stem cells
Cancer Medicine · 2023-09 · 12 (18) · 18960-18980
DOI: 10.1002/cam4.6520 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 12.09.2023. Verfasst von Amirhossein Izadpanah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran…. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Accumulating data reveals that tumors possess a specialized subset of cancer cells named cancer stem cells (CSCs), responsible for metastasis and recurrence of malignancies, with various properties such as self‐renewal, heterogenicity, and capacity for drug resistance. Some signaling pathways or processes like Notch, epithelial to mesenchymal transition (EMT), Hedgehog (Hh), and Wnt, as well as CSCs' surface markers such as CD44, CD123, CD133, and epithelial cell adhesion molecule (EpCAM) have pivotal roles in acquiring CSCs properties. Therefore, targeting CSC‐related signaling pathways and surface markers might effectively eradicate tumors and pave the way for cancer survival. Since current treatments such as chemotherapy and radiation therapy cannot eradicate all of the CSCs and tumor relapse may happen following temporary recovery, improving novel and more efficient therapeutic options to combine with current treatments is required. Immunotherapy strategies are the new therapeutic modalities with promising results in targeting CSCs. Here, we review the targeting of CSCs by immunotherapy strategies such as dendritic cell (DC) vaccines, chimeric antigen receptors (CAR)‐engineered immune cells, natural killer‐cell (NK‐cell) therapy, monoclonal antibodies (mAbs), checkpoint inhibitors, and the use of oncolytic viruses (OVs) in pre‐clinical and clinical studies. This review will mainly focus on blood malignancies but also describe solid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Molecular Cell Biology-Genetics, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
- Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Arefeh Saeedian
Zitieren
APA
Izadpanah, A., Mohammadkhani, N., Masoudnia, M., Ghasemzad, M., Saeedian, A., Mehdizadeh, H., Poorebrahim, M., & Ebrahimi, M. (2023). Update on immune‐based therapy strategies targeting cancer stem cells. Cancer Medicine, 12(18), 18960-18980. https://doi.org/10.1002/cam4.6520
Vancouver
Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H, et al. Update on immune‐based therapy strategies targeting cancer stem cells. Cancer Medicine. 2023;12(18):18960-18980. doi:10.1002/cam4.6520
BibTeX
@article{Izadpanah2023,
author = {Izadpanah, Amirhossein and Mohammadkhani, Niloufar and Masoudnia, Mina and Ghasemzad, Mahsa and Saeedian, Arefeh and Mehdizadeh, Hamid and Poorebrahim, Mansour and Ebrahimi, Marzieh},
title = {Update on immune‐based therapy strategies targeting cancer stem cells},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {18},
pages = {18960--18980},
doi = {10.1002/cam4.6520}
}
EUVIMED